What´s it worth and does it add value on ONT-10 etc . To me it´s encouraging that after such a study there was detected notable treatment effect.
Notable is a strong word, which is good... But the intent to treat population may be smaller.
I wonder how the clinical hold messed with results.
I guess Merck will let more info out in a few months.
I definitely will hold my shares for ONT-10 and the other Stimuvax studies Merck is running.
Disappointed and down, but not out.
It does seem obvious from the wording of the statement that Stimuvax does
do something positive and work to a point------just not for the end goal
of this specific trial. Definitely not a total loss----especially for cancer victims.
Basically what it means is that the drug works (has it´s positive effect) but the design of the study was wrong, we were looking for a wrong thing and maybe in a wrong place.